Search research articles
Contact Us
Filters
Showing results (31-40 of 143) with videos related to
Page
of 15
Sort By:
Current Opinion in Immunology
|
September 22, 2012
Genetic modification of lymphocytes by retrovirus-based vectors
Julia D Suerth, Axel Schambach, Christopher Baum
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
November 3, 2010
Transatlantic consortium spotlights need for changes in gene therapy trials
David A Williams, Adrian J Thrasher, Christopher Baum
Human Gene Therapy
|
January 15, 2013
Biosafety features of lentiviral vectors
Axel Schambach, Daniela Zychlinski, Birgitta Ehrnstroem, et al.
Stem Cells (Dayton, Ohio)
|
September 8, 2011
Concise review: managing genotoxicity in the therapeutic modification of stem cells
Christopher Baum, Ute Modlich, Gudrun Göhring, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
April 25, 2006
Retrovirus vectors: toward the plentivirus?
Christopher Baum, Axel Schambach, Jens Bohne, et al.
The Journal of Clinical Investigation
|
October 7, 2004
Lenti in red: progress in gene therapy for human hemoglobinopathies
Christof von Kalle, Christopher Baum, David A Williams
Toxicology
|
February 12, 2002
The cytotoxic effect of mistletoe lectins I, II and III on sensitive and multidrug resistant human colon cancer cell lines in vitro
Ursula Valentiner, Uwe Pfüller, Christopher Baum, et al.
Viruses
|
October 14, 2011
Gammaretroviral vectors: biology, technology and application
Tobias Maetzig, Melanie Galla, Christopher Baum, et al.
Expert Opinion on Biological Therapy
|
June 10, 2010
Generation and genetic modification of induced pluripotent stem cells
Axel Schambach, Tobias Cantz, Christopher Baum, et al.
Journal of Virology
|
January 18, 2008
Cellular restriction of retrovirus particle-mediated mRNA transfer
Melanie Galla, Axel Schambach, Greg J Towers, et al.
Page
of 15
Search research articles
Search
Showing results (31-40 of 143) with videos related to
Sort By:
Page
of 15
Current Opinion in Immunology
|
September 22, 2012
Genetic modification of lymphocytes by retrovirus-based vectors
Julia D Suerth, Axel Schambach, Christopher Baum
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
November 3, 2010
Transatlantic consortium spotlights need for changes in gene therapy trials
David A Williams, Adrian J Thrasher, Christopher Baum
Human Gene Therapy
|
January 15, 2013
Biosafety features of lentiviral vectors
Axel Schambach, Daniela Zychlinski, Birgitta Ehrnstroem, et al.
Stem Cells (Dayton, Ohio)
|
September 8, 2011
Concise review: managing genotoxicity in the therapeutic modification of stem cells
Christopher Baum, Ute Modlich, Gudrun Göhring, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
April 25, 2006
Retrovirus vectors: toward the plentivirus?
Christopher Baum, Axel Schambach, Jens Bohne, et al.
The Journal of Clinical Investigation
|
October 7, 2004
Lenti in red: progress in gene therapy for human hemoglobinopathies
Christof von Kalle, Christopher Baum, David A Williams
Toxicology
|
February 12, 2002
The cytotoxic effect of mistletoe lectins I, II and III on sensitive and multidrug resistant human colon cancer cell lines in vitro
Ursula Valentiner, Uwe Pfüller, Christopher Baum, et al.
Viruses
|
October 14, 2011
Gammaretroviral vectors: biology, technology and application
Tobias Maetzig, Melanie Galla, Christopher Baum, et al.
Expert Opinion on Biological Therapy
|
June 10, 2010
Generation and genetic modification of induced pluripotent stem cells
Axel Schambach, Tobias Cantz, Christopher Baum, et al.
Journal of Virology
|
January 18, 2008
Cellular restriction of retrovirus particle-mediated mRNA transfer
Melanie Galla, Axel Schambach, Greg J Towers, et al.
Page
of 15